Market Overview

UPDATE: Credit Suisse Initiates Baxter International at Outperform on Solid Top-Line Growth

Related BAX
Baxter Submits Application for U.S. FDA Approval of BAX111, Investigational Recombinant Treatment for Von Willebrand Disease
Baxter to Divest Vero Cell Vaccines Platform to Nanotherapeutics
Merck Snags Baxter Executive As CFO (Fox Business)

In a report published Wednesday, Credit Suisse analyst Bruce Nudell initiated coverage on Baxter International (NYSE: BAX) with an Outperform rating and $81.00 price target.

In the report, Credit Suisse noted, “We see BAX's solid top-line growth (4.6% organic growth in 2012-15, 1% ahead of large-cap med-tech peers) and dividend prospects (2.8% yield, ~1% above peers), combined with in line valuation (on a P/E and PEG basis), as supportive of an Outperform rating. Our $81 DCF-derived target price (17.5 and 15.7 times our 2013-14 EPS estimates) assumes an 8.5% WACC and 1.5% terminal growth rate.”

Baxter International closed on Tuesday at $71.45.

Latest Ratings for BAX

DateFirmActionFromTo
Oct 2014BarclaysMaintainsOverweight
Oct 2014Credit SuisseMaintainsOutperform
Oct 2014Morgan StanleyMaintainsEqual-weight

View More Analyst Ratings for BAX
View the Latest Analyst Ratings

Posted-In: Bruce Nudell Credit SuisseAnalyst Color Initiation Analyst Ratings

 

Related Articles (BAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters